Dalriada brings in former Evotec executive Adam Davenport to lead strategy execution as Chief R&D Officer
Toronto, ON, May 3rd, 2023 – Dalriada, a leading Canadian contract research organization specializing in small molecule therapies, announces today that it has strengthened its executive leadership team, appointing Adam Davenport, Ph.D. as its Chief Research & Development Officer (CRDO).